On Valentine’s Day, BioSpace would be remiss not to mention, er, matters of the heart. There are reportedly 59 life sciences companies or organizations worldwide that focus on the cardiovascular system, ranging from the Aab Cardiovascular Research Institute based in West Henrietta, New York to XyloCor Therapeutics, with headquarters in Philadelphia. That number is probably low.
Treatment with Stelara is resulting in positive outcomes for patients with Crohn’s disease, as Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.
Florida-based Catalyst Pharmaceuticals is attempting to show in court that the price of a newly approved treatment for a rare autoimmune disease and pressure from U.S. Sen. Bernie Sanders lead to the approval of a rival treatment.
A Phase III trial is planned after promising results were revealed from Dana-Farber Cancer Institute for MK-6482 in advanced clear cell kidney cancer.
The U.S. Food and Drug Administration called for Eisai to pull the company’s Belviq and Belviq XR for weight loss from the market after clinical trials demonstrated an increased incidence of cancer in users.
Novacyt plans to launch a certified test for the coronavirus, sending the biotechnology company’s London-listed shares to a record high.
